Hyloris Pharmaceuticals Statistics
Total Valuation
Hyloris Pharmaceuticals has a market cap or net worth of EUR 168.00 million. The enterprise value is 139.06 million.
Market Cap | 168.00M |
Enterprise Value | 139.06M |
Important Dates
The next estimated earnings date is Tuesday, September 10, 2024.
Earnings Date | Sep 10, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Hyloris Pharmaceuticals has 28.00 million shares outstanding.
Shares Outstanding | 28.00M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 56.83% |
Owned by Institutions (%) | 0.27% |
Float | 12.09M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 39.87 |
PB Ratio | 4.30 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -9.04 |
EV / Sales | 33.00 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -10.61 |
Financial Position
The company has a current ratio of 5.22, with a Debt / Equity ratio of 4.48.
Current Ratio | 5.22 |
Quick Ratio | 5.14 |
Debt / Equity | 4.48 |
Debt / EBITDA | n/a |
Debt / FCF | -0.13 |
Interest Coverage | -304.73 |
Financial Efficiency
Return on equity (ROE) is -33.08% and return on invested capital (ROIC) is -20.72%.
Return on Equity (ROE) | -33.08% |
Return on Assets (ROA) | -18.27% |
Return on Capital (ROIC) | -20.72% |
Revenue Per Employee | 102,780 |
Profits Per Employee | -375,122 |
Employee Count | 41 |
Asset Turnover | 0.08 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.26% in the last 52 weeks. The beta is 0.45, so Hyloris Pharmaceuticals's price volatility has been lower than the market average.
Beta (5Y) | 0.45 |
52-Week Price Change | -50.26% |
50-Day Moving Average | 9.00 |
200-Day Moving Average | 11.47 |
Relative Strength Index (RSI) | 39.04 |
Average Volume (20 Days) | 42,639 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hyloris Pharmaceuticals had revenue of EUR 4.21 million and -15.38 million in losses. Loss per share was -0.55.
Revenue | 4.21M |
Gross Profit | 4.12M |
Operating Income | -15.85M |
Pretax Income | -15.38M |
Net Income | -15.38M |
EBITDA | -15.74M |
EBIT | -15.85M |
Loss Per Share | -0.55 |
Balance Sheet
The company has 30.91 million in cash and 1.75 million in debt, giving a net cash position of 29.15 million or 1.04 per share.
Cash & Cash Equivalents | 30.91M |
Total Debt | 1.75M |
Net Cash | 29.15M |
Net Cash Per Share | 1.04 |
Equity (Book Value) | 39.07M |
Book Value Per Share | 1.40 |
Working Capital | 28.55M |
Cash Flow
In the last 12 months, operating cash flow was -12.81 million and capital expenditures -298,000, giving a free cash flow of -13.11 million.
Operating Cash Flow | -12.81M |
Capital Expenditures | -298,000 |
Free Cash Flow | -13.11M |
FCF Per Share | -0.47 |
Margins
Gross Margin | 97.79% |
Operating Margin | -376.03% |
Pretax Margin | -364.97% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -311.01% |
Dividends & Yields
Hyloris Pharmaceuticals does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -9.17% |
FCF Yield | -7.80% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |